^
    Back
    Association details:
    Biomarker:FGFR1 amplification
    Cancer:HER2 Negative Breast Cancer
    Drug:pazopanib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Natl Compr Canc Netw
    Title:

    Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification

    Excerpt:
    This report presents a patient with metastatic HR+ HER2- breast cancer harboring an FGFR1 amplification who was resistant to endocrine therapy but responded to pazopanib, a multi-tyrosine kinase inhibitor with FGFR-inhibiting activity.
    DOI:
    10.6004/jnccn.2017.7030